Demographics of control and non-small cell lung cancer (NSCLC) groups.

Snapshot img

Non-Small Cell Lung Cancer Drugs Market Size 2024-2028

The non-small cell lung cancer (NSCLC)drugs market size is forecast to increase by USD 21.06 billion at a CAGR of 10.87% between 2023 and 2028.

The non-small cell lung cancer (NSCLC) drug market is experiencing significant growth due to several factors. The increasing prevalence of NSCLC, driven by air pollution and smoking behaviors, is a major market driver. Additionally, the approval and introduction of combination therapies, such as those involving HER2-positive gastric and gastroesophageal (GEJ) adenocarcinoma medications, are contributing to market expansion.
However, the high cost of NSCLC treatment poses a challenge to market growth. Daiichi Sankyo and other pharmaceutical companies are focusing on developing new treatments, including Fruquintinib (HMPL-013) and PD-L1 antibody therapies, to address this need and meet the demands of the growing patient population.

What will be the Non-Small Cell Lung Cancer Drugs Market Size During the Forecast Period?

Request Free Sample

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. The NSCLC drugs market encompasses various treatment modalities, including small molecules, biologics, alkylating agents, antimetabolites, mitotic inhibitors, multi-kinase inhibitors, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The NSCLC drugs market has seen significant advancements in recent years, driven by the development of innovative treatment options. Small molecules and biologics have been the primary focus of research and development (R&D) efforts due to their targeted approach and improved efficacy. The pipeline for NSCLC drugs is strong, with several promising candidates in various stages of clinical development. One such candidate is Fruquintinib (HMPL-013), a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, which is currently under investigation for the treatment of advanced NSCLC. Another promising development is the use of PD-L1 antibodies in immunotherapy, which has shown promising results in clinical trials.
The diagnosis and treatment of NSCLC involve various modalities, including CT scans and radiation therapy. Radiation oncologists play a crucial role in the management of NSCLC patients, using advanced technologies such as deep learning systems to optimize radiation therapy plans. The risk factors for NSCLC include a history of smoking, exposure to air pollution, and occupational hazards such as asbestos and arsenic. The availability and accessibility of these drugs depend on various factors, including insurance coverage, geographic location, and patient demographics. The NSCLC drugs market is expected to continue growing due to the increasing prevalence of the disease and the development of new and innovative treatment options. The use of advanced technologies such as deep learning systems and targeted therapies is expected to drive the growth of the market in the coming years.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Adenocarcinoma
  Squamous cell carcinoma
  Large cell carcinoma


Product

  Biologics
  Small molecule targeted therapy
  Chemotherapy


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Type Insights

The adenocarcinoma segment is estimated to witness significant growth during the forecast period.

Adenocarcinoma is a type of cancer that develops in the glandular tissue, which produces and secretes substances into the body. This form of cancer affects various organs, including the breast, lungs, esophagus, stomach, colon, rectum, pancreas, prostate, and uterus. Several factors contribute to the development of adenocarcinoma. Smoking is a significant risk factor for adenocarcinoma, making it a leading cause of this disease. Exposure to toxins in the home or work environment can also contribute to its development. Previous radiation therapy is another risk factor, increasing the likelihood of adenocarcinoma. In Massachusetts, researchers are developing innovative solutions to combat adenocarcinoma.

For instance, a deep learning system has been designed to analyze CT scans and assist radiation oncologists in diagnosing and treating the disease more accurately. Additionally, companies like Moderna and Rain Therapeutics are exploring the use of messenger RNA (mRNA) and anti-TIM-3 antibody, respectively, for targeted therapy. These advancements in technology and pharmaceuticals offer hope for improving life expectancy for patients diagnosed with adenocarcinoma. By c

Incidence rate differences per 1000 person-years, and crude and adjusted hazard ratios overall and category-specific for first-time potential PNS among patients with NSCLC and with SCLC compared with general population.

Market Size and Growth: The PD-1 Non Small Cell Lung Cancer Treatment Market is valued at $674.52 million in 2025 and is projected to reach $1,129.10 million by 2033, exhibiting a CAGR of 6.44% during the forecast period. Rising prevalence of non-small cell lung cancer, growing awareness of PD-1 inhibitors, and increasing government funding for cancer research are key factors driving market growth. Key Trends and Segmentation: Monoclonal antibodies and combination therapies dominate the market, with intravenous administration being the preferred route. Adjuvant therapy accounts for the largest share in the treatment phase segment. Hospitals and specialty clinics account for the majority of the end user market. North America holds the largest market share, followed by Europe. Asia Pacific is expected to witness substantial growth due to increasing cancer diagnosis rates and improving healthcare infrastructure. Key players include Roche, Janssen Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly, who are actively involved in research and development of innovative PD-1 inhibitors. Recent developments include: Recent developments in the PD-1 Non-Small Cell Lung Cancer Treatment Market reflect significant advancements and strategic movements by key players. Roche has announced enhancements to its PD-1 inhibitor portfolio, which are expected to bolster its market presence. Janssen Pharmaceuticals has indicated progress in clinical trials, demonstrating the promising efficacy of its innovative therapies. Bristol Myers Squibb is also gaining attention with ongoing research that showcases the potential of combination therapies, strengthening its competitive edge in treating non-small cell lung cancer. Pfizer and Regeneron Pharmaceuticals are exploring collaborative opportunities to enhance treatment outcomes and expand patient access. On the merger and acquisition front, notable movements include AstraZeneca's acquisition of a biotech company that complements its PD-1 offerings, strengthening its strategic position in this area. Growth in market valuation is primarily observed through the increased adoption of PD-1 inhibitors, with companies like Amgen and Genentech noting enhanced revenue streams attributed to their robust treatment portfolios. This competitive landscape emphasizes innovation and strategic partnerships, reflecting an optimistic outlook for the PD-1 non-small cell lung cancer treatment sector as companies strive to address unmet medical needs and improve patient outcomes.. Key drivers for this market are: Rising incidence of non-small cell lung cancer, Increased adoption of immunotherapy; Expanding target patient population; Advancement in combination therapies; Growth in biomarker testing technologies. Potential restraints include: Rising cancer prevalence, Increased R investments; Growing healthcare expenditure; Advancements in immunotherapy; Expanding patient awareness.

We analyzed NSCLC data from the Surveillance, Epidemiology, and End Results database, focusing on lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC).

Lung Cancer Diagnostic Tests Market Outlook

The lung cancer diagnostic tests market size was valued at USD 2.5 billion in 2023 and is projected to reach USD 6.1 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 10.5% during the forecast period. This substantial growth can be attributed to the rising prevalence of lung cancer globally, advancements in diagnostic technologies, and increasing awareness regarding early detection and treatment of lung cancer. The growing aging population and the high incidence of smoking, which is a leading cause of lung cancer, further propel the demand for diagnostic tests.

The increasing prevalence of lung cancer is one of the primary drivers of market growth. Lung cancer remains the leading cause of cancer-related deaths worldwide, necessitating the development of more accurate and early diagnostic methods. With advancements in medical technology, such as molecular diagnostics and non-invasive imaging techniques, the accuracy and efficiency of lung cancer diagnosis have significantly improved. These innovations not only enhance the detection rate but also facilitate personalized treatment plans, thereby improving patient outcomes.

Furthermore, government initiatives and funding for cancer research play a crucial role in market expansion. Many countries are investing heavily in cancer research, leading to the development of new diagnostic tools and techniques. For instance, organizations such as the National Cancer Institute (NCI) in the United States provide substantial grants for lung cancer research, fostering innovations in diagnostics. In addition, public awareness campaigns and screening programs conducted by healthcare organizations and governments encourage early diagnosis, which is vital for successful treatment and survival rates.

The integration of artificial intelligence (AI) and machine learning in diagnostic tools is another significant factor contributing to market growth. AI algorithms can analyze medical images with high precision, aiding radiologists in identifying lung cancer at earlier stages. Moreover, AI-driven software can evaluate large datasets from genetic and molecular tests, providing insights into the most effective treatment options based on individual patient profiles. This technological advancement not only enhances the accuracy of diagnostics but also reduces the time required for analysis, thereby increasing the efficiency of healthcare services.

The EGFR Mutation Test is a pivotal advancement in the realm of lung cancer diagnostics, offering a more personalized approach to treatment. This test specifically identifies mutations in the Epidermal Growth Factor Receptor (EGFR) gene, which are often present in non-small cell lung cancer (NSCLC) patients. By detecting these mutations, healthcare providers can tailor therapies that target the specific genetic alterations, thereby improving treatment efficacy and patient outcomes. The growing adoption of EGFR Mutation Tests underscores the shift towards precision medicine, where treatments are increasingly customized based on individual genetic profiles. This approach not only enhances the effectiveness of therapies but also minimizes adverse effects, as treatments are more accurately aligned with the patient's unique genetic makeup.

Regionally, North America holds the largest share of the lung cancer diagnostic tests market, followed by Europe and Asia Pacific. The dominance of North America can be attributed to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a robust research landscape. The Asia Pacific region, however, is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare investments, growing awareness about lung cancer, and rising incidences of the disease in countries like China and India. The growing middle-class population and improving healthcare access in these countries further support market growth.

Test Type Analysis

The lung cancer diagnostic tests market is segmented by test type into imaging tests, sputum cytology, tissue biopsy, molecular tests, and others. Imaging tests are one of the most commonly used diagnostic methods for lung cancer detection. Techniques such as X-rays, CT scans, and PET scans provide detailed visuals of the lungs, helping in identifying abnormal growths or tumors. The non-invasive nature of these tests and their ability to provide quick results make them a preferred choice among healthcare

The Non-Small Cell Lung Cancer Market is estimated to be valued at USD 11.5 billion in 2025 and is projected to reach USD 23.0 billion by 2035, registering a compound annual growth rate (CAGR) of 7.2% over the forecast period.

The Non-Small Cell Lung Cancer (NSCLC) treatment market has emerged as a critical sector within the oncology landscape, driven by the rising incidence of lung cancer globally and the shifting paradigms in therapeutic approaches. NSCLC accounts for approximately 85% of all lung cancer cases, and its management encomp

The size of the Non-Small Cell Lung Cancer (NSCLC) market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 9.50% during the forecast period. Recent developments include: In January 2023, Novocure reported that the LUNAR study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together with standard therapies for stage 4 non-small cell lung cancer (NSCLC) following progression while on or after treatment with platinum-based therapy, met its primary endpoint., In December 2022, the United States FDA granted accelerated approval to Mirati's Krazati (adagrasib), a targeted treatment option for adult patients with KRAS-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).. Key drivers for this market are: Increasing Investment for the Development of New Therapy, Increasing Prevalence of NSCLC. Potential restraints include: High Cost of Therapy/Drugs and Low Diagnosis Rate in Developing Countries. Notable trends are: Targeted Therapy Segment is Expected to Hold Significant Market Share Over the Forecast Period.

A Comprehensive Lung Cancer Structured Clinical Dataset:

Lung cancer is a type of cancer that begins in the lungs, often associated with smoking but also linked to factors like air pollution, genetic predisposition, and exposure to toxins such as asbestos and radon. It is one of the leading causes of cancer-related deaths globally, as it is often diagnosed in advanced stages.

There are two main types: Non-Small Cell Lung Cancer (NSCLC), the most common form, and Small Cell Lung Cancer (SCLC), which is more aggressive but less common.

Symptoms include persistent cough, shortness of breath, chest pain, and unexplained weight loss.

Early detection through screenings such as low-dose CT scans significantly improves outcomes. Treatment options include surgery, chemotherapy, radiation, immunotherapy, and targeted therapies, tailored to the cancer's type and stage.

Preventive measures like avoiding smoking and reducing exposure to environmental risk factors are key to reducing lung cancer incidence.

Data Images are not in dcm format, the images are in jpg or png to fit the model Data contain 3 chest cancer types which are Adenocarcinoma,Large cell carcinoma, Squamous cell carcinoma , and 1 folder for the normal cell Data folder is the main folder that contain all the step folders inside Data folder are test , train , valid

test represent testing set train represent training set valid represent validation set training set is 70% testing set is 20% validation set is 10%

Adenocarcinoma Adenocarcinoma of the lung: Lung adenocarcinoma is the most common form of lung cancer accounting for 30 percent of all cases overall and about 40 percent of all non-small cell lung cancer occurrences. Adenocarcinomas are found in several common cancers, including breast, prostate and colorectal. Adenocarcinomas of the lung are found in the outer region of the lung in glands that secrete mucus and help us breathe. Symptoms include coughing, hoarseness, weight loss and weakness.

Large cell carcinoma Large-cell undifferentiated carcinoma: Large-cell undifferentiated carcinoma lung cancer grows and spreads quickly and can be found anywhere in the lung. This type of lung cancer usually accounts for 10 to 15 percent of all cases of NSCLC. Large-cell undifferentiated carcinoma tends to grow and spread quickly. ** Squamous cell carcinoma** Squamous cell: This type of lung cancer is found centrally in the lung, where the larger bronchi join the trachea to the lung, or in one of the main airway branches. Squamous cell lung cancer is responsible for about 30 percent of all non-small cell lung cancers, and is generally linked to smoking.

And the last folder is the normal CT-Scan images

Acknowledgements We wouldn't be here without the help of others and the resources we found. thanks for all of my team and the people who supported us

Inspiration I want to hear all your feedback

Non-Small Cell Lung Cancer Immunotherapies Market Outlook

According to our latest research, the Non-Small Cell Lung Cancer Immunotherapies market size reached USD 12.8 billion globally in 2024, reflecting a robust expansion driven by advancements in immunotherapeutic approaches and rising incidence rates of lung cancer worldwide. The market is projected to grow at a CAGR of 12.4% from 2025 to 2033, with the forecasted market size expected to attain USD 36.6 billion by 2033. This growth is primarily attributed to the increasing adoption of immune checkpoint inhibitors, improved survival outcomes, and a growing focus on precision medicine within oncology.

The surge in the Non-Small Cell Lung Cancer Immunotherapies market is strongly propelled by the rising prevalence of non-small cell lung cancer (NSCLC) globally, which accounts for approximately 85% of all lung cancer cases. The growing burden of NSCLC, particularly among aging populations and individuals with a history of smoking, has heightened the demand for innovative and effective treatment modalities. Immunotherapies have emerged as a cornerstone in the management of advanced NSCLC, offering improved progression-free and overall survival rates compared to conventional chemotherapy. Additionally, the increasing awareness among both patients and healthcare providers regarding the benefits of immunotherapy, such as reduced toxicity and durable responses, has further fueled market expansion.

Another critical growth factor for the Non-Small Cell Lung Cancer Immunotherapies market is the rapid pace of research and development activities in the field of oncology. Pharmaceutical companies and research institutions are heavily investing in the discovery and clinical development of novel immunotherapeutic agents, including immune checkpoint inhibitors, monoclonal antibodies, and cancer vaccines. The approval of breakthrough therapies by regulatory authorities, such as the US FDA and EMA, has accelerated the adoption of these treatments in clinical practice. Furthermore, the integration of biomarker-driven approaches and companion diagnostics has enabled the identification of patients most likely to benefit from immunotherapies, thereby optimizing treatment outcomes and expanding the eligible patient pool.

The market is also witnessing significant growth due to the increasing number of strategic collaborations, partnerships, and mergers among key players in the biotechnology and pharmaceutical sectors. These collaborations are aimed at leveraging complementary expertise, expanding research pipelines, and accelerating the commercialization of innovative immunotherapies for NSCLC. Moreover, supportive government initiatives, rising healthcare expenditure, and the expansion of reimbursement coverage for immunotherapy drugs are contributing to the market's positive trajectory. The entry of biosimilars and next-generation immunotherapeutic agents is expected to further intensify competition and drive down treatment costs, making these advanced therapies more accessible to a broader patient population.

The development of Non-small Cell Lung Cancer Therapeutics has been pivotal in transforming the treatment landscape for patients with this prevalent form of lung cancer. These therapeutics encompass a range of modalities, including targeted therapies, chemotherapy, and the increasingly important immunotherapies. The focus on precision medicine has enabled the tailoring of treatments to individual patient profiles, enhancing efficacy and minimizing adverse effects. As research continues to unravel the complexities of NSCLC, novel therapeutic options are being explored, offering hope for improved survival and quality of life for patients. The integration of these therapeutics into clinical practice is supported by robust clinical trial data and the ongoing collaboration between pharmaceutical companies and research institutions.

From a regional perspective, North America continues to dominate the Non-Small Cell Lung Cancer Immunotherapies market, accounting for the largest revenue share due to the presence of well-established healthcare infrastructure, high adoption rates of advanced therapies, and a strong focus on clinical research. Europe follows closely, supported by favorable regulatory frameworks and increasing inve

NSCLC remains to be the leading cause of cancer incidence and mortality in the Philippines. Early diagnosis, better understanding on the mechanisms of drug resistance, and proper treatment monitoring is necessary to lower the incidence and mortality rate of NSCLC. This study was able to provide initial insights on the proteomic profile of Filipino NSCLC by quantitative proteomic analysis and identification of aberrant expressions in the tumor tissue relative to the adjacent normal tissue specimen. A total of 4518 proteins were identified and from this, 1855 proteins were found to be significantly upregulated and downregulated. Functional and pathway analysis was done to the upregulated and downregulated proteins with at least 4-fold expression change. Pathway analysis revealed the possible activation of the upregulated protein, MUC1, which is a known oncogenic driver involved in the stimulation of pathways that promote angiogenesis in NSCLC tumor, and prevention of apoptosis. STAT1 and STAT3, also found upregulated in the tumor specimen, were known to have interactions with MUC1 which results to expression of proteins for cell proliferation. The analysis also suggests the stabilization of HIF which allows cell growth in the hypoxic tumor environment, and the activation of EIF signaling correlated with low survival rate of NSCLC patients. Our data demonstrate the rich proteomic information that can be obtained from comprehensive profiling of the NSCLC proteome and applications for better understanding of NSCLC tumorigenicity.

Non-Small Cell Lung Cancer Immunotherapies Market Outlook

According to our latest research, the global Non-Small Cell Lung Cancer (NSCLC) Immunotherapies market size reached USD 12.4 billion in 2024, with a robust compound annual growth rate (CAGR) of 13.2% observed over recent years. The growth trajectory is expected to continue, and by 2033, the market is forecasted to attain a value of USD 36.1 billion. This significant market expansion is primarily driven by increasing incidence rates of NSCLC, advancements in immunotherapy technologies, and rising adoption of personalized medicine approaches worldwide. As per our latest research, the industry is experiencing rapid innovation and investment, fueling both clinical and commercial progress.

The primary growth factor for the Non-Small Cell Lung Cancer Immunotherapies market is the rising global burden of lung cancer, which remains one of the leading causes of cancer-related mortality. NSCLC accounts for approximately 85% of all lung cancer cases, making it a critical area for therapeutic intervention. The increasing prevalence of risk factors such as smoking, air pollution, and occupational hazards has contributed to a higher incidence of NSCLC, especially in rapidly urbanizing regions. This surge in patient populations has intensified demand for effective treatment modalities, propelling the adoption of immunotherapies that offer improved survival rates and better quality of life compared to conventional chemotherapy. The growing awareness about early detection and the availability of advanced diagnostic tools also support the expansion of the NSCLC immunotherapies market.

Another crucial driver is the continuous innovation and clinical success of immunotherapeutic agents, particularly immune checkpoint inhibitors and monoclonal antibodies. Over the past decade, significant breakthroughs in understanding the tumor microenvironment and immune evasion mechanisms have led to the development of novel drugs targeting specific checkpoints such as PD-1, PD-L1, and CTLA-4. These therapies have demonstrated remarkable efficacy in prolonging patient survival and reducing disease progression, even in advanced-stage NSCLC. The increasing number of regulatory approvals for new immunotherapies, coupled with ongoing clinical trials exploring combination regimens, has created a dynamic pipeline that promises sustained market growth. Furthermore, collaborations between pharmaceutical companies and academic institutions have accelerated the translation of research into commercially viable treatments.

The expanding focus on personalized and precision medicine is also shaping the Non-Small Cell Lung Cancer Immunotherapies market. Advances in genomic profiling and biomarker discovery have enabled the identification of patient subgroups most likely to benefit from specific immunotherapies, optimizing treatment outcomes and minimizing adverse effects. The integration of companion diagnostics into clinical practice allows for tailored therapeutic strategies, which not only enhance efficacy but also drive market adoption. Additionally, the growing investment in healthcare infrastructure, particularly in emerging economies, is facilitating greater access to cutting-edge immunotherapies. Governments and private stakeholders are increasingly prioritizing cancer care, resulting in improved reimbursement policies and expanded clinical trial networks.

Regionally, North America continues to dominate the Non-Small Cell Lung Cancer Immunotherapies market, accounting for the largest revenue share in 2024. This leadership is attributed to the region’s advanced healthcare infrastructure, high awareness levels, and substantial investments in research and development. However, Asia Pacific is emerging as the fastest-growing market, driven by rising cancer incidence, improving healthcare access, and increasing adoption of innovative therapies. Europe also holds a significant share, supported by strong regulatory frameworks and active participation in clinical research. Latin America and the Middle East & Africa are witnessing gradual growth, spurred by government initiatives and expanding pharmaceutical presence. The global landscape is characterized by a mix of established and emerging markets, each contributing uniquely to the overall expansion of the NSCLC immunotherapies sector.

Therapy Type Analysis

The Therapy Type segment of the Non-Small

The Non-small Cell Lung Cancer (NSCLC) therapeutics market is a significant and rapidly evolving landscape, driven by increasing prevalence of NSCLC, advancements in targeted therapies and immunotherapies, and a growing understanding of the disease's complex genetic drivers. The market, estimated at $100 billion in 2025, is projected to experience robust growth with a Compound Annual Growth Rate (CAGR) of approximately 8% from 2025 to 2033. This growth is fueled by the continuous development and approval of novel therapies, including targeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), and antibody-drug conjugates (ADCs), offering improved efficacy and patient outcomes compared to traditional chemotherapy. Key players like GlaxoSmithKline, Novartis, AstraZeneca, Roche, Bristol-Myers Squibb, Pfizer, Eli Lilly, and Sanofi are heavily investing in R&D, expanding their portfolios, and engaging in strategic partnerships to capitalize on this market opportunity. The market segmentation by application reflects the diverse treatment approaches available, ranging from first-line therapies to maintenance and later-line treatments, tailored to specific patient characteristics and tumor mutations. Regional variations exist, with North America and Europe currently dominating the market due to higher healthcare expenditure, advanced healthcare infrastructure, and greater awareness among patients and physicians. However, emerging economies in Asia Pacific, particularly China and India, are exhibiting significant growth potential, driven by rising incidence rates and increased access to advanced medical technologies. Market restraints include the high cost of novel therapies, the development of drug resistance, and the need for improved early detection and diagnosis strategies. Addressing these challenges through innovative payment models, improved patient access programs, and ongoing research into resistance mechanisms will be crucial in maximizing the long-term growth potential of the NSCLC therapeutics market. The forecast period from 2025 to 2033 presents a compelling investment opportunity within this dynamic and essential sector of the pharmaceutical industry.

Non-small cell lung cancer is one of the most common cancers and the leading cause of cancer death worldwide. Genetic variants in regulatory regions of some miRNAs might be involved in non-small cell lung cancer susceptibility and survival. rs12220909 (G/C) genetic polymorphism in miR-4293 has been shown to be associated with decreased risk of esophageal squamous cell carcinoma. However, the influence of rs12220909 genetic variation on non-small cell lung cancer susceptibility has not been reported. In order to evaluate the potential association between miR-4293 rs12220909 and non-small cell lung cancer risk in a Chinese population, we performed a case-control study among 998 non-small cell lung cancer cases and 1471 controls. The data shows that miR-4293 rs12220909 was significantly associated with decreased susceptibility to non-small cell lung cancer (GC vs.GG: OR = 0.681, 95%CI = 0.555–0.835, P = 2.19E-4; GG vs. GC+CC: OR = 0.687, 95%CI = 0.564–0.837, P = 1.95E-4), which indicates that rs12220909 in miR-4293 may play a significant role in the development of non-small cell lung cancer.

Data are presented as number, or median and data range. COPD: chronic obstructive pulmonary disease; Smoking history: cur: current, ex: ex-smokers, no: never smoked; Lung Cancer: presence of lung cancer; NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer; Type of NSCLC: adeno: adenocarcinoma, squa: squamous cell carcinoma, larg: large cell carcinoma; Radiation therapy: cur: current, pre: previous exposure, no: never exposed; Chemotherapy: cur: current, pre: previous exposure, no: never exposed; Pky: smoking pack years;fev1: forced expiratory volume in one second, % pred: percentage of predicted; fvc: forced vital capacity.*: significant difference from control group, p<0.05. Note that one COPD patient was classified as ‘mild COPD’, with a fev1/fvc of 67.Patient demographics.

The Non-Small Cell Lung Carcinoma (NSCLC) Market is estimated to be valued at USD 10.0 billion in 2025 and is projected to reach USD 25.9 billion by 2035, registering a compound annual growth rate (CAGR) of 10.0% over the forecast period.

As per Cognitive Market Research's latest published report, the Global Non-Small Cell Lung Cancer Treatment market size was $24,912.7 million in 2022. Non-Small Cell Lung Cancer Treatment Industry's Compound Annual Growth Rate will be 9.5% from 2023 to 2030. What is Driving Non-Small Cell Lung Cancer Treatment Market?

The growth in the rate of consumption of tobacco by a young group of people, severe air pollution, and unhealthy lifestyle are forecasted to dominate the global market. In addition, an increase in the new drug approval for non-small cell lung cancer treatment is another factor that drives the demand for the global market.

Non-small Cell Lung Cancer Treatment Market Opportunity

The development of diversified therapies such as chemotherapy, and radiation therapy to treat early-stage small cell lung cancer will provide an opportunity for the global market.

Non-small Cell Lung Cancer Treatment Market Restraints

However, the high cost of non-small cell lung cancer treatment negatively impacts the growth of the global non-small cell lung cancer treatment market. Furthermore, strict government regulations for product approval may hamper the target market growth. Introduction of Non-Small Cell Lung Cancer Treatment

Non-small cell lung cancer is a form of lung cancer in which the lungs produce malignant tumor cells. It includes groups of various diseases, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma that exhibit similar behaviors. Non-small cell lung cancers such as adenocarcinomas are more prevalent in younger people than older persons and in women than in males. Those with a history of smoking and those who are exposed to contaminated air are more likely to have it than persons who smoke regularly.

Demographic and clinical characteristics of NSCLC patients(n = 245).